2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure

Chun Chieh Wang, Cho Kai Wu, Ming Lung Tsai, Chii Ming Lee, Wei Chun Huang, Hsin Hua Chou, Jin Long Huang, Nai Hsin Chi, Hsueh Wei Yen, Bing Hsiean Tzeng, Wei Ting Chang, Hung Yu Chang, Chao Hung Wang, Yen Yu Lu, Jui Peng Tsai, Chun Hung Su, Wen Jin Cherng, Wei Hsian Yin, Chia Ti Tsai, Yen Wen WuJiunn-Lee Lin, Juey Jen Hwang

Research output: Contribution to journalArticle

Abstract

Heart failure is a growing epidemic, especially in Taiwan because of the aging population. The 2016 Taiwan Society of Cardiology - Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry showed that the guidelinerecommended therapies were prescribed suboptimally both at the time of hospital discharge and during followup. We, therefore, conducted this 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure to reinforce the importance of new diagnostic and therapeuticmodalities of heart failure. The 2019 focused update discusses new diagnostic criteria, pharmacotherapy, non-pharmacological management, and certain co-morbidities of heart failure. Angiotensin receptor neprilysin inhibitor and If channel inhibitor is introduced as new and recommended medical therapies. Latest criteria of cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, and ventricular assist device therapy are reviewed in the non-pharmacological management chapter. Co-morbidities in heart failure are discussed including chronic kidney disease, diabetes, chronic obstructive pulmonary disease, and sleep-disordered breathing.We also explain the adequate use of oxygen therapy and non-invasive ventilation in heart failure management. A particular chapter for chemotherapy-induced cardiac toxicity is incorporated in the focused update to emphasize the importance of its recognition and management. Lastly, implications from the TSOC-HFrEF registry and post-acute care of heart failure are discussed to highlight the importance of guideline-directed medical therapy and the benefits of multidisciplinary disease management programs. With guideline recommendations, we hope that the management of heart failure can be improved in our society.

Original languageEnglish
Pages (from-to)244-283
Number of pages40
JournalActa Cardiologica Sinica
Volume35
Issue number3
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Cardiology
Treatment Failure
Taiwan
Heart Failure
Guidelines
Heart-Assist Devices
Registries
Subacute Care
Morbidity
Therapeutics
Noninvasive Ventilation
Drug Therapy
Neprilysin
Cardiac Resynchronization Therapy
Angiotensin Receptors
Implantable Defibrillators
Sleep Apnea Syndromes
Heart Transplantation
Disease Management
Chronic Renal Insufficiency

Keywords

  • Biomarkers
  • Cardiac resynchronization therapy
  • Cardio-oncology
  • Co-morbidities
  • Guidelines
  • Heart failure
  • Pharmacotherapy
  • Post-acute care
  • Transplantation
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure. / Wang, Chun Chieh; Wu, Cho Kai; Tsai, Ming Lung; Lee, Chii Ming; Huang, Wei Chun; Chou, Hsin Hua; Huang, Jin Long; Chi, Nai Hsin; Yen, Hsueh Wei; Tzeng, Bing Hsiean; Chang, Wei Ting; Chang, Hung Yu; Wang, Chao Hung; Lu, Yen Yu; Tsai, Jui Peng; Su, Chun Hung; Cherng, Wen Jin; Yin, Wei Hsian; Tsai, Chia Ti; Wu, Yen Wen; Lin, Jiunn-Lee; Hwang, Juey Jen.

In: Acta Cardiologica Sinica, Vol. 35, No. 3, 01.05.2019, p. 244-283.

Research output: Contribution to journalArticle

Wang, CC, Wu, CK, Tsai, ML, Lee, CM, Huang, WC, Chou, HH, Huang, JL, Chi, NH, Yen, HW, Tzeng, BH, Chang, WT, Chang, HY, Wang, CH, Lu, YY, Tsai, JP, Su, CH, Cherng, WJ, Yin, WH, Tsai, CT, Wu, YW, Lin, J-L & Hwang, JJ 2019, '2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure', Acta Cardiologica Sinica, vol. 35, no. 3, pp. 244-283. https://doi.org/10.6515/ACS.201905_35(3).20190422A
Wang, Chun Chieh ; Wu, Cho Kai ; Tsai, Ming Lung ; Lee, Chii Ming ; Huang, Wei Chun ; Chou, Hsin Hua ; Huang, Jin Long ; Chi, Nai Hsin ; Yen, Hsueh Wei ; Tzeng, Bing Hsiean ; Chang, Wei Ting ; Chang, Hung Yu ; Wang, Chao Hung ; Lu, Yen Yu ; Tsai, Jui Peng ; Su, Chun Hung ; Cherng, Wen Jin ; Yin, Wei Hsian ; Tsai, Chia Ti ; Wu, Yen Wen ; Lin, Jiunn-Lee ; Hwang, Juey Jen. / 2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure. In: Acta Cardiologica Sinica. 2019 ; Vol. 35, No. 3. pp. 244-283.
@article{6d5078400acd49249bb48c2b248e052b,
title = "2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure",
abstract = "Heart failure is a growing epidemic, especially in Taiwan because of the aging population. The 2016 Taiwan Society of Cardiology - Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry showed that the guidelinerecommended therapies were prescribed suboptimally both at the time of hospital discharge and during followup. We, therefore, conducted this 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure to reinforce the importance of new diagnostic and therapeuticmodalities of heart failure. The 2019 focused update discusses new diagnostic criteria, pharmacotherapy, non-pharmacological management, and certain co-morbidities of heart failure. Angiotensin receptor neprilysin inhibitor and If channel inhibitor is introduced as new and recommended medical therapies. Latest criteria of cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, and ventricular assist device therapy are reviewed in the non-pharmacological management chapter. Co-morbidities in heart failure are discussed including chronic kidney disease, diabetes, chronic obstructive pulmonary disease, and sleep-disordered breathing.We also explain the adequate use of oxygen therapy and non-invasive ventilation in heart failure management. A particular chapter for chemotherapy-induced cardiac toxicity is incorporated in the focused update to emphasize the importance of its recognition and management. Lastly, implications from the TSOC-HFrEF registry and post-acute care of heart failure are discussed to highlight the importance of guideline-directed medical therapy and the benefits of multidisciplinary disease management programs. With guideline recommendations, we hope that the management of heart failure can be improved in our society.",
keywords = "Biomarkers, Cardiac resynchronization therapy, Cardio-oncology, Co-morbidities, Guidelines, Heart failure, Pharmacotherapy, Post-acute care, Transplantation, Ventricular assist device",
author = "Wang, {Chun Chieh} and Wu, {Cho Kai} and Tsai, {Ming Lung} and Lee, {Chii Ming} and Huang, {Wei Chun} and Chou, {Hsin Hua} and Huang, {Jin Long} and Chi, {Nai Hsin} and Yen, {Hsueh Wei} and Tzeng, {Bing Hsiean} and Chang, {Wei Ting} and Chang, {Hung Yu} and Wang, {Chao Hung} and Lu, {Yen Yu} and Tsai, {Jui Peng} and Su, {Chun Hung} and Cherng, {Wen Jin} and Yin, {Wei Hsian} and Tsai, {Chia Ti} and Wu, {Yen Wen} and Jiunn-Lee Lin and Hwang, {Juey Jen}",
year = "2019",
month = "5",
day = "1",
doi = "10.6515/ACS.201905_35(3).20190422A",
language = "English",
volume = "35",
pages = "244--283",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "3",

}

TY - JOUR

T1 - 2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure

AU - Wang, Chun Chieh

AU - Wu, Cho Kai

AU - Tsai, Ming Lung

AU - Lee, Chii Ming

AU - Huang, Wei Chun

AU - Chou, Hsin Hua

AU - Huang, Jin Long

AU - Chi, Nai Hsin

AU - Yen, Hsueh Wei

AU - Tzeng, Bing Hsiean

AU - Chang, Wei Ting

AU - Chang, Hung Yu

AU - Wang, Chao Hung

AU - Lu, Yen Yu

AU - Tsai, Jui Peng

AU - Su, Chun Hung

AU - Cherng, Wen Jin

AU - Yin, Wei Hsian

AU - Tsai, Chia Ti

AU - Wu, Yen Wen

AU - Lin, Jiunn-Lee

AU - Hwang, Juey Jen

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Heart failure is a growing epidemic, especially in Taiwan because of the aging population. The 2016 Taiwan Society of Cardiology - Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry showed that the guidelinerecommended therapies were prescribed suboptimally both at the time of hospital discharge and during followup. We, therefore, conducted this 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure to reinforce the importance of new diagnostic and therapeuticmodalities of heart failure. The 2019 focused update discusses new diagnostic criteria, pharmacotherapy, non-pharmacological management, and certain co-morbidities of heart failure. Angiotensin receptor neprilysin inhibitor and If channel inhibitor is introduced as new and recommended medical therapies. Latest criteria of cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, and ventricular assist device therapy are reviewed in the non-pharmacological management chapter. Co-morbidities in heart failure are discussed including chronic kidney disease, diabetes, chronic obstructive pulmonary disease, and sleep-disordered breathing.We also explain the adequate use of oxygen therapy and non-invasive ventilation in heart failure management. A particular chapter for chemotherapy-induced cardiac toxicity is incorporated in the focused update to emphasize the importance of its recognition and management. Lastly, implications from the TSOC-HFrEF registry and post-acute care of heart failure are discussed to highlight the importance of guideline-directed medical therapy and the benefits of multidisciplinary disease management programs. With guideline recommendations, we hope that the management of heart failure can be improved in our society.

AB - Heart failure is a growing epidemic, especially in Taiwan because of the aging population. The 2016 Taiwan Society of Cardiology - Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry showed that the guidelinerecommended therapies were prescribed suboptimally both at the time of hospital discharge and during followup. We, therefore, conducted this 2019 focused update of the guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure to reinforce the importance of new diagnostic and therapeuticmodalities of heart failure. The 2019 focused update discusses new diagnostic criteria, pharmacotherapy, non-pharmacological management, and certain co-morbidities of heart failure. Angiotensin receptor neprilysin inhibitor and If channel inhibitor is introduced as new and recommended medical therapies. Latest criteria of cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, and ventricular assist device therapy are reviewed in the non-pharmacological management chapter. Co-morbidities in heart failure are discussed including chronic kidney disease, diabetes, chronic obstructive pulmonary disease, and sleep-disordered breathing.We also explain the adequate use of oxygen therapy and non-invasive ventilation in heart failure management. A particular chapter for chemotherapy-induced cardiac toxicity is incorporated in the focused update to emphasize the importance of its recognition and management. Lastly, implications from the TSOC-HFrEF registry and post-acute care of heart failure are discussed to highlight the importance of guideline-directed medical therapy and the benefits of multidisciplinary disease management programs. With guideline recommendations, we hope that the management of heart failure can be improved in our society.

KW - Biomarkers

KW - Cardiac resynchronization therapy

KW - Cardio-oncology

KW - Co-morbidities

KW - Guidelines

KW - Heart failure

KW - Pharmacotherapy

KW - Post-acute care

KW - Transplantation

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=85069864171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069864171&partnerID=8YFLogxK

U2 - 10.6515/ACS.201905_35(3).20190422A

DO - 10.6515/ACS.201905_35(3).20190422A

M3 - Article

AN - SCOPUS:85069864171

VL - 35

SP - 244

EP - 283

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 3

ER -